Ingredient Beauty BenefitsPeptide · Acetyl Hexapeptide-8
Argireline: it is called 'Botox in a bottle', and no trial has compared it with botulinum toxin
In a 60-person placebo-controlled trial, periorbital wrinkles improved significantly. But **the placebo group improved 0%**, a figure rarely seen in cosmetic trials. And **we found no trial comparing this ingredient directly with botulinum toxin.**
Last checked Sep 17, 2026
- In pregnancy
- Not established
- Irritation
- Minimal
- Daytime use
- ✓ Fine
Not a measurement — reported irritation grouped into five steps. It varies between people.
Acetyl hexapeptide-8 is a synthetic peptide of six amino acids, better known by the trade name Argireline.
The naming needs sorting out first. The papers we read spell it differently: the 2013 paper says 'argireline', the 2024 paper says 'acetyl hexapeptide-8, also known as Argireline', and the 2023 paper says 'Acetylhexapeptide-3'. Ingredient lists carry both -3 and -8.
The mechanism goes like this. Botulinum toxin stops muscle contraction by preventing the SNARE complex from forming at the nerve ending; this peptide is patterned on one end of a protein in that complex (SNAP-25) and is said to interfere at the same place.
A plausible mechanism and a demonstrated effect are different things. Read what follows in that order.
Contents
What is established
The same ingredient at a different strength, in a different formula, is a different product. These are the conditions the studies used.
Periorbital roughness fell in a 60-person trial
A 2013 randomised, placebo-controlled study in China. Sixty subjects were allocated 3 to 1 to argireline or placebo and applied it to periorbital wrinkles twice daily for four weeks.
Assessment ran on two tracks.
- Subjective (global assessment using established classifications): total anti-wrinkle efficacy 48.9% in the argireline group against 0% in the placebo group.
- Objective (silicone replicas of the treated skin read by a wrinkle-analysis apparatus): roughness parameters all decreased in the argireline group (p < .01), with no obvious decrease in placebo.
The silicone-replica measurement is the firmest evidence this ingredient has — a device reading rather than a human eye.
But 0% in the placebo group is hard to walk past. In cosmetic trials, a good share of people improve on vehicle alone: in the 1996 trial on this site's glycolic acid page, 40% of the vehicle group improved by at least one grade. A placebo response of exactly zero can mean a very strict grading scheme, imperfect blinding, or simply a small group.
And 3-to-1 allocation puts about 15 people in the placebo arm. Zero out of 15 does not mean what zero out of 60 would.
The concentration is not in the abstract, which is why the concentration field here is empty: we do not know what percentage produced this result.
- Randomised controlled trial in people · 60 participants · 4 weeks · Compared with vehicle (same formula minus the active) · Funding not declared · Endpoint instrument measurement PMID 23417317
Put against another peptide, it came second
A 2023 double-blind randomised trial in Indonesia. Twenty-one women aged 26 to 55 were split into three groups — acetyl hexapeptide-3 cream, palmitoyl pentapeptide-4 cream, and placebo — applied twice daily to the periorbital area for eight weeks.
Palmitoyl pentapeptide-4 did better than acetyl hexapeptide-3, on the data, the clinical photographs and the self-assessment questionnaire alike, as the authors put it.
This should not be read as settled. Twenty-one people across three groups is seven per arm, and the authors themselves concluded that further study with a more adequate sample size and duration was needed.
The direction is still worth remembering. This ingredient is far more famous than the other one thanks to its nickname — but when the two met in the same trial, the less famous one won.
- Randomised controlled trial in people · 21 participants · 8 weeks · Compared with vehicle (same formula minus the active) · Funding not declared · Endpoint scores from blinded assessors PMID 36909866
We found no trial comparing it with botulinum toxin
A 2024 paper analysed public interest in this ingredient, tracking Google search volume in the United States from 2013 to 2023.
The finding: the terms 'Argireline' and 'Botox in a Bottle' both rose substantially in 2022. 'Argireline' was still searched less than 'Botox'. The authors attributed the rise to affordability, over-the-counter availability and ease of self-application.
What this paper does on this page is not supply efficacy evidence. It documents how widely the nickname has spread.
And the comparison that nickname implies has never been tested. We found no trial putting this ingredient directly against botulinum toxin.
Why such a comparison is hard is worth stating. Botulinum toxin is injected into muscle. This peptide is applied to the skin surface. Even granting the same mechanistic target, they arrive in different places — and whether a peptide crosses the stratum corneum to reach a nerve ending is itself something that has to be shown. This site raises the same question on the palmitoyl pentapeptide-4 page.
On this site, botulinum toxin sits in the procedures layer. That separation is exactly why.
How to use it
- Most products do not disclose the amount, and neither does the evidence. The 2013 abstract gives no concentration.
- The trials above ran 4–8 weeks. Judging sooner is hard.
- It rarely irritates, which makes it easy to use on thin skin such as around the eyes. All the trials above were done there.
- Look for both -3 and -8 on ingredient lists. The papers mix the two spellings too.
Cautions
- Irritation reports are rare.
- We found no established data on use during pregnancy.
- Carrying a wrinkle functional claim with this ingredient requires review in Korea. Annex 4 lists only retinol, retinyl palmitate, adenosine and polyethoxylated retinamide for wrinkles; no peptide is on it.
- 'Botox in a bottle' on a label is a nickname, not evidence.
With a new ingredient, apply a small amount somewhere inconspicuous, such as the inner arm, for two days first. Stop if it reddens or stings.
Related skin concerns
What this article relies on
- PubMed — 미국 국립의학도서관 문헌 데이터베이스National Library of Medicine · Checked on 2026-09-16